**Name of Journal:** *World Journal of Nephrology*

**Manuscript NO:** 57178

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Findings on intraprocedural non-contrast computed tomographic imaging following hepatic artery embolization are associated with development of contrast-induced nephropathy**

Soliman MM *et al.* Hepatic artery embolization and development of CIN

Mohamed M Soliman, Debkumar Sarkar, Ilya Glezerman, Majid Maybody

**Mohamed M Soliman, Debkumar Sarkar, Majid Maybody,** Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States

**Ilya Glezerman,** Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States

**Author contributions:** Soliman MM contributed toanalysis and interpretation of data, drafting of manuscript, critical revision; Sarkar D contributed to acquisition of data, analysis and interpretation of data, critical revision; Glezerman I contributed to study conception and design, analysis and interpretation of data, critical revision; Maybody M contributed to study conception and design, acquisition of data, analysis and interpretation of data, drafting of manuscript, critical revision.

**Supported by** the NIH/NCI Cancer Center, No. P30 CA008748.

**Corresponding author: Majid Maybody, MD, Associate Professor,** Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, M276C, New York, NY 10065, United States. [maybodym@mskcc.org](mailto:maybodym@mskcc.org)

**Received:** May 27, 2020

**Revised:** August 19, 2020

**Accepted:** September 14, 2020

**Published online:**

**Abstract**

BACKGROUND

Contrast-induced nephropathy (CIN) is a reversible form of acute kidney injury that occurs within 48-72 h of exposure to intravascular contrast material. CIN is the third leading cause of hospital-acquired acute kidney injury and accounts for 12% of such cases. Risk factors for CIN development can be divided into patient- and procedure-related. The former includes pre-existing chronic renal insufficiency and diabetes mellitus. The latter includes high contrast volume and repeated exposure over 72 h. The incidence of CIN is relatively low (up to 5%) in patients with intact renal function. However, in patients with known chronic renal insufficiency, the incidence can reach up to 27%.

AIM

To examine the association between renal enhancement pattern on non-contrast enhanced computed tomographic (CT) images obtained immediately following hepatic artery embolization with development of CIN.

METHODS

Retrospective review of all patients who underwent hepatic artery embolization between 01/2010 and 01/2011 (*n* = 162) was performed. Patients without intraprocedural CT imaging (*n* = 51), combined embolization/ablation (*n* = 6) and those with chronic kidney disease (*n* = 21) were excluded. The study group comprised of 84 patients with 106 procedures. CIN was defined as 25% increase above baseline serum creatinine or absolute increase ≥ 0.5 mg/dL within 72 h post-embolization. Post-embolization CT was reviewed for renal enhancement patterns and presence of renal artery calcifications. The association between non-contrast CT findings and CIN development was examined by Fisher’s Exact Test.

RESULTS

CIN occurred in 11/106 (10.3%) procedures (Group A, *n* = 10). The renal enhancement pattern in patients who did not experience CIN (Group B, *n* = 74 with 95/106 procedures) was late excretory in 93/95 (98%) and early excretory (EE) in 2/95 (2%). However, in Group A, there was a significantly higher rate of EE pattern (6/11, 55%) compared to late excretory pattern (5/11) (*P* < 0.001). A significantly higher percentage of patients that developed CIN had renal artery calcifications (6/11 *vs* 20/95, 55% *vs* 21%, *P* = 0.02).

CONCLUSION

A hyperdense renal parenchyma relative to surrounding skeletal muscle (EE pattern) and presence of renal artery calcifications on immediate post-HAE non-contrast CT images in patients with low risk for CIN are independently associated with CIN development.

**Key Words:** Hepatic artery embolization; Non-contrast computed tomographic; Contrast-induced nephropathy; Renal enhancement pattern; Intra-arterial; Renal artery calcification

Soliman MM, Sarkar D, Glezerman I, Maybody M. Findings on intraprocedural non-contrast computed tomographic imaging following hepatic artery embolization are associated with development of contrast-induced nephropathy. *World J Nephrol* 2020; In press

**Core Tip:** Contrast-induced nephropathy (CIN) is a reversible form of acute kidney injury that occurs within 48-72 h of exposure to intravascular contrast material. CIN is the third leading cause of hospital-acquired acute kidney injury and accounts for 12% of such cases. Identification of early indicators of CIN development is important in taking timely management strategies. There is no known mechanism for early identification and timely initiation of preventive measures in patients otherwise considered low risk for development of CIN after transarterial hepatic artery embolization. This work helps clinicians identify patients at risk of CIN at the time of hepatic artery embolization.

**INTRODUCTION**

Contrast-induced nephropathy (CIN) is a reversible form of acute kidney injury (AKI) that occurs within 48-72 h of exposure to intravascular contrast material[1]. The most widely accepted definition of CIN is a 25% increase in serum creatinine (sCr) concentration from baseline sCr, or an absolute increase of at least 0.5 mg/dL which appears within 48-72 h after contrast media exposure, is maintained for 3-5 d and returns to baseline over 7-10 d, after excluding other causes[2,3].

CIN is the third leading cause of hospital-acquired AKI and accounts for 12% of such cases[4]. Risk factors for CIN development can be divided into patient- and procedure-related. The former includes pre-existing chronic renal insufficiency and diabetes mellitus. The latter includes high contrast volume and repeated exposure over 72 h[4-7]. The incidence of CIN is relatively low (up to 5%) in patients with intact renal function[8]. However, in patients with known chronic renal insufficiency, the incidence can reach up to 27%[8]. CIN more commonly develops following intraarterial contrast exposure (*e.g.*, diagnostic arteriograms, coronary interventions, transarterial therapies) than with peripheral intravenous administration (*e.g.*, computed tomography)[9,10]. Although the acute decline of renal function in CIN is reversible within 1-2 wk, a higher 1-mo and 1-year mortality rates have been reported in those patients, particularly following arterial angiography[11,12].

Identification of early indicators of CIN development is important in taking timely management strategies. The elevation in sCr occurs 2-3 d following contrast exposure, and is a poorly-timed indicator[13,14]. Persistent renal enhancement after intravenous or intraarterial contrast administration on non-contrast enhanced computed tomographic (CT) images obtained within 7 d post-contrast exposure has been associated with development of CIN[15]. There is no known mechanism for early identification and timely initiation of preventive measures in patients otherwise considered low risk for development of CIN after transarterial hepatic artery embolization[16-18].

When available, a non-contrast CT or cone beam CT imaging of upper abdomen is routinely performed at the end of hepatic artery embolization (HAE) to assess contrast retention pattern in embolized tumors as a surrogate for treatment response[19-21]. This volume of imaging also covers the kidneys. The aim of this study is to identify early predictors for CIN by examining the appearance of kidneys on non-contrast intraprocedural CT images.

**MATERIALS AND METHODS**

***Patient selection***

The local Institutional Review Board approved this retrospective review (Protocol 16-402) of all patients who underwent HAE between January 2010 and January 2011. Informed consent from individual patients for the retrospective review was waived.

For the hepatic artery embolization procedure for treatment of primary or secondary hepatic malignancies, all patients were chosen based on multidisciplinary consensus and were seen in a dedicated outpatient interventional radiology clinic, where history, laboratory tests and imaging were reviewed. Eligibility for transarterial HAE was based on clinical status and laboratory test results (Child-Pugh A or B, Total serum bilirubin < 2 mg/dL, Eastern Coorpative Oncology Group performance status < 3). The type of embolization (bland *vs* chemoembolization) was based on multidisciplinary consensus. Informed consent was obtained for HAE from all patients prior to the procedure.

***Inclusion and exclusion criteria***

All patients who underwent HAE for treatment of primary or secondary hepatic malignancies within the defined time period were included in the study (*n* = 162). A total of 217 procedures were performed. Based on the procedure suite, post-embolization non-contrast CT images were available in 139/217 (64%) procedures. Patients with known chronic kidney disease (CKD) stage 3 or higher [GFR < 60 mL/min/1.72 m2 using the CKD-EPI formula] were excluded (*n* = 21) since they are typically admitted for IV fluid hydration prior to the procedure and are at high risk for CIN. Patients who underwent percutaneous ablation in combination to embolization were excluded due to delay in post embolization non-contrast CT acquisition (*n* = 6). A total of 84 patients (106 procedures) were included in the final analysis (Figure 1).

***Data collection***

Patient electronic records were reviewed for age, gender, ethnicity, type of liver malignancy, presence and etiology of cirrhosis, presence of medical comorbidities related to chronic kidney disease (diabetes mellitus, hypertension, coronary artery disease, prior history of contrast allergies, and number of embolization procedures performed. Laboratory test results were reviewed for sCr prior to embolization, and post-embolization peak sCr in the first 72 h following embolization. Procedural details including type of embolization (bland *vs* chemoembolization), total contrast volume administered, and total procedure duration (defined by total sedation or anesthesia time) were recorded. CIN was defined as 25% increase in sCr above baseline or an absolute increase of ≥ 0.5 mg/dL in sCr within 72 h of embolization. Patients were divided into two groups based on the change in post-embolization sCr: Group A developed CIN and Group B did not develop CIN. Immediate post-embolization non-contrast CT images was reviewed for renal enhancement pattern and presence of renal artery calcifications. All data was compiled in a Health Insurance Portability and Accountability Act-compliant database.

Patient demographics are recorded in Table 1. A total of 84 patients (53 males, 31 females; mean age 63 years, range: 29-87 years) with 106 procedures were included in the final analysis.

***Hepatic artery embolization and CT acquisition***

Pre-procedural imaging was reviewed prior to the procedure. General endotracheal anesthesia (*n* = 85) or conscious sedation (*n* = 21) were used. Patients were prepped and draped in a standard sterile fashion. Following ultrasound (US)-guided common femoral artery access and utilizing Seldinger technique, a 5 French guide catheter was advanced through a 6 French vascular sheath into the origin of the celiac axis or superior mesenteric artery. Angiograms were obtained using Iohexol (Omnipaque 300; GE Healthcare, Marlborough, MA, United States). A 2.4-2.8 French microcatheter was advanced over a micro guidewire co-axially through the guide catheter for superselective catherization of target branches based on angiographic findings and predetermined area of treatment. Treatment was done with either Embospheres (Merit Medical, South Jordan, UT, United States), Embozene (Boston Scientific, Burlington, MA, United States) and Poly-Vinyl Alcohol particles under continuous angiographic monitoring until complete arterial stasis was achieved. Hemostasis was obtained with a femoral closure device. All patients underwent bland HAE with an average procedural duration of 111.8 min, and average total administered contrast volume of 174.3 mL (average, median, range; Group A: 155, 152.5, 50-320 mL. Group B: 161, 150, 58-350 mL). Post-embolization non-contrast CT was obtained immediately after achieving hemostasis (10-20 min after embolization completion) in all study patients. Patients were transferred to the post-anesthesia care unit and were subsequently admitted for symptomatic management of post-embolization syndrome.

***Non-contrast CT analysis***

The assessment of renal enhancement pattern and presence of renal artery calcifications was performed by two independent readers. In the case of disagreement, a third reader was involved to assess the CT findings. Regions-of-interest were drawn on the renal cortex, medulla and pelvis to accurately determine the phase or pattern of renal enhancement and categorize them based on predetermined thresholds as either: corticomedullary, nephrographic, early excretory (EE) or late excretory (LE) (Figures 2 and 3)[22,23]. Corticomedullary pattern occurs 25-80 s after contrast injection and is defined by intense enhancement of the renal cortex relative to the renal medulla, with a difference in Hounsfield units (HU) approaching 100 HU. Nephrographic pattern occurs 85-120 s after contrast injection and is defined by homogenous enhancement of the renal parenchyma (cortex and medulla) with HU range of 120-170. The excretory patterns occur 3-5 min after contrast injection. EE pattern is defined by the opacification of the renal calyces/pelvis, with hyperdense renal parenchyma relative to surrounding skeletal muscle. LE pattern is defined by a renal parenchyma iso-dense to skeletal muscle, with contrast fully opacifying the renal pelvis and ureter. Due to timing of post HAE intraprocedural CT imaging (10-20 min after completion of embolization), the corticomedullary and nephrographic patterns were not seen in our patient cohort. Renal enhancement pattern was divided into only 2 later patterns of EE or LE. Any discernible plaque along the renal arteries with more than 130 Hounsfield units were considered calcifications (Figure 4)

***Statistical analysis***

Descriptive statistics (mean, standard deviation) were used to describe the patient demographics and procedural details. Continuous data are reported as the mean value ± SD. A Mann-Whitney U Test was performed to examine difference in baseline serum creatinine, and total contrast volume and procedure duration between the two patient groups. A Fisher’s Exact Test was utilized to compare the prevalence of diabetes mellitus amongst the two patient groups. The association between renal enhancement pattern, presence of renal artery calcifications and the development of CIN (Group A *vs* B) were analyzed by Chi-Square test of Independence. *P* value 0.05 was considered to indicate statistical significance. All analyses were performed with SPSS statistical software version 12.0 (SPSS, Inc., Chicago, IL, United States).

**RESULTS**

There was no significant difference between the baseline sCr (*P* = 0.46), total contrast volume administered (*P* = 0.61), total procedure duration (*P* = 0.25), or prevalence of diabetes mellitus (*P* = 0.38) amongst the two groups.

The renal enhancement patterns are recorded in Table 2. In patients who did not experience CIN (Group B, *n* = 74 with 95 procedures) the renal enhancement pattern was late excretory in 93/95 procedures (98%) and early excretory in 2/95 procedures (2%). CIN occurred following 11/106 (11.2%) procedures in 10 distinct patients (Group A). In this group, there was a significantly higher rate of early excretory renal enhancement (6/11 procedures, 55%) compared to late excretory pattern (5/11 procedures, 45%) (*P <* 0.001). Renal artery calcifications were detected in 26 post-embolization non-contrast CT scans. A significantly higher percentage of patients that developed CIN had detectable renal artery calcifications (6/11 *vs* 20/95, 55% *vs* 21% respectively, *P* = 0.01).

Patients in Group A were hospitalized for a median of 4 d post-embolization (IQR: 3-10 d). Peak sCr was reached in a median of 2 d post-embolization (IQR: 1-2.5 d). Those who stayed in the hospital for 2 d or longer (*n* = 9) demonstrated complete normalization of sCr prior to discharge. No patient required hemodialysis or hemofiltration. One patient required a nephrology consultation due to oliguria despite Foley catheter placement.

**DISCUSSION**

The findings of this study suggest an association between the renal enhancement pattern on the immediate post-HAE non-contrast enhanced CT imaging and the development of CIN in low-risk patients. It also suggests an association between renal artery calcifications and development of CIN.

The cornerstone of CIN management is prevention. Risk stratification, IV fluid administration and avoidance of nephrotoxic medications are all essential in prevention[24]. Randomized clinical trials have consistently shown the efficacy of IV fluid hydration in the prevention of CIN in high-risk patient populations[25-28]. All investigated fluid regimens included a pre-procedural component and a post-procedural component (*e.g.*, IV 0.9% normal saline 12 h pre-HAE and 12- h post-HAE). The consensus is that both components contribute to volume expansion and prevention of CIN development[24]. No head-to-head study was performed investigating the efficacy of pre-procedural hydration compared to post-procedural hydration.

High-risk patients are followed by nephrologists in the outpatient setting, are typically admitted the day before an interventional procedure for IV fluid administration and are followed by nephrologists during their admission and after discharge. Conversely, low-risk patients typically arrive on the day of the procedure and no special renal protective precautions are taken.

Currently there is no mechanism for early identification and timely initiation of preventive measures for patients who do not have risk factors for development of CIN after transarterial hepatic artery embolization[16-18]. In this study, we propose that risk stratification could be initiated within the interventional radiology procedure room. The proposed method is simple with no need for any calculations or image processing. If in a patient low risk for development of CIN, the renal parenchyma is hyperdense compared to adjacent skeletal muscle at the end of hepatic artery embolization, preventive measures should be initiated immediately. In this group of low-risk patients with no history of CKD, CIN or contrast-allergies, an early excretory pattern on the post-embolization CT imaging was associated with the development of CIN. In addition, the presence of renal artery calcifications was found to be independently associated with CIN development. This is in agreement with prior studies showing the association of renal artery calcification with renal function[29,30]. Renal artery calcification can be identified prior to embolization intervention by reviewing CT scan of abdomen. These patients should be treated like those at risk for CIN with pre and post procedural hydration. For those patients stratified based on immediate post procedural CT imaging renal enhancement patterns, a nephrology consultation should be initiated, along with rapid initiation of IV fluid hydration to prevent CIN development. These patients should also be marked for preventive measures for their future angiographic interventions.

This study has several limitations. Inherent to its retrospective design and small sample size, extensive multivariable logistic regression and analysis of potential confounders are limited. The method used to determine renal enhancement patterns is not free of subjectivity despite utilization of multiple readers. Furthermore, the exact timing of non-contrast CT acquisition was variable and could be a potential confounder.

Larger, prospective studies should be conducted with standardized post-HAE CT acquisition timing to investigate this association.

Hyperdense renal parenchyma relative to surrounding skeletal muscle (Early excretory renal enhancement pattern) on immediate post HAE non-contrast CT images and also the presence of renal artery calcification are associated with the development of CIN.

**CONCLUSION**

Hyperdense renal parenchyma relative to surrounding skeletal muscle (Early excretory renal enhancement pattern) on immediate post HAE non-contrast CT images and also the presence of renal artery calcification are associated with the development of CIN.

**ARTICLE HIGHLIGHTS**

***Research background***

Contrast-induced nephropathy (CIN) is a reversible form of acute kidney injury that occurs within 48-72 h of exposure to intravascular contrast material. A higher 1-mo and 1-year mortality rates have been reported in these patients, particularly following arterial angiography.

***Research motivation***

The cornerstone of CIN management is prevention.

***Research objectives***

To help with early identification and timely initiation of preventive measures in patients otherwise considered low risk for development of CIN after transarterial hepatic artery embolization.

***Research methods***

Retrospective review of all patients who underwent hepatic artery embolization between 2010 and 2011 (*n* = 162) was performed. After removing exclusions, the study group comprised of 84 patients with 106 procedures. CIN was defined as 25% increase above baseline serum creatinine or absolute increase ≥ 0.5 mg/dL within 72 h post-embolization. Post-embolization computed tomographic (CT) was reviewed for renal enhancement patterns and presence of renal artery calcifications. The association between non-contrast CT findings and CIN development was examined by Fisher’s Exact Test.

***Research results***

CIN occurred in 11/106 (10.3%) procedures (Group A, *n* = 10). The renal enhancement pattern in patients who did not experience CIN (Group B, *n* = 74 with 95/106 procedures) was late excretory in 93/95 (98%) and early excretory (EE) in 2/95 (2%). However, in Group A, there was a significantly higher rate of EE pattern (6/11, 55%) compared to late excretory pattern (5/11) (*P* <0.001). A significantly higher percentage of patients that developed CIN had renal artery calcifications (6/11 *vs* 20/95, 55% *vs* 21%, *P* = 0.02).

***Research conclusions***

A hyperdense renal parenchyma relative to surrounding skeletal muscle (EE pattern) and presence of renal artery calcifications on immediate post-HAE non-contrast CT images in patients with low risk for CIN are independently associated with CIN development.

***Research perspectives***

Prospective studies are required to further assess the findings of this study.

**REFERENCES**

1 **Parfrey PS**, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, Farid N, McManamon PJ. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. *N Engl J Med* 1989; **320**: 143-149 [PMID: 2643041 DOI: 10.1056/NEJM198901193200303]

2 **Goldenberg I**, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. *CMAJ* 2005; **172**: 1461-1471 [PMID: 15911862 DOI: 10.1503/cmaj.1040847]

3 **Gleeson TG**, Bulugahapitiya S. Contrast-induced nephropathy. *AJR Am J Roentgenol* 2004; **183**: 1673-1689 [PMID: 15547209 DOI: 10.2214/ajr.183.6.01831673]

4 **Hou SH**, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. *Am J Med* 1983; **74**: 243-248 [PMID: 6824004 DOI: 10.1016/0002-9343(83)90618-6]

5 **Mehran R**, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. *Kidney Int Suppl* 2006; S11-S15 [PMID: 16612394 DOI: 10.1038/sj.ki.5000368]

6 **McCullough PA**, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, Tumlin J; CIN Consensus Working Panel. Risk prediction of contrast-induced nephropathy. *Am J Cardiol* 2006; **98**: 27K-36K [PMID: 16949378 DOI: 10.1016/j.amjcard.2006.01.022]

7 **Mehran R**, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol* 2004; **44**: 1393-1399 [PMID: 15464318 DOI: 10.1016/j.jacc.2004.06.068]

8 **Morcos SK**, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). *Eur Radiol* 1999; **9**: 1602-1613 [PMID: 10525875 DOI: 10.1007/s003300050894]

9 **Kooiman J**, Pasha SM, Zondag W, Sijpkens YW, van der Molen AJ, Huisman MV, Dekkers OM. Meta-analysis: serum creatinine changes following contrast enhanced CT imaging. *Eur J Radiol* 2012; **81**: 2554-2561 [PMID: 22177326 DOI: 10.1016/j.ejrad.2011.11.020]

10 **Karlsberg RP**, Dohad SY, Sheng R; Iodixanol Peripheral CTA Study Investigator Panel. Contrast-induced acute kidney injury (CI-AKI) following intra-arterial administration of iodinated contrast media. *J Nephrol* 2010; **23**: 658-666 [PMID: 20540038]

11 **Coca SG**, Peixoto AJ, Garg AX, Krumholz HM, Parikh CR. The prognostic importance of a small acute decrement in kidney function in hospitalized patients: a systematic review and meta-analysis. *Am J Kidney Dis* 2007; **50**: 712-720 [PMID: 17954284 DOI: 10.1053/j.ajkd.2007.07.018]

12 **Lindsay J**, Canos DA, Apple S, Pinnow E, Aggrey GK, Pichard AD. Causes of acute renal dysfunction after percutaneous coronary intervention and comparison of late mortality rates with postprocedure rise of creatine kinase-MB *vs* rise of serum creatinine. *Am J Cardiol* 2004; **94**: 786-789 [PMID: 15374790 DOI: 10.1016/j.amjcard.2004.06.007]

13 **Tublin ME**, Murphy ME, Tessler FN. Current concepts in contrast media-induced nephropathy. *AJR Am J Roentgenol* 1998; **171**: 933-939 [PMID: 9762972 DOI: 10.2214/ajr.171.4.9762972]

14 **Mohammed NM**, Mahfouz A, Achkar K, Rafie IM, Hajar R. Contrast-induced Nephropathy. *Heart Views* 2013; **14**: 106-116 [PMID: 24696755 DOI: 10.4103/1995-705X.125926]

15 **Chou SH**, Wang ZJ, Kuo J, Cabarrus M, Fu Y, Aslam R, Yee J, Zimmet JM, Shunk K, Elicker B, Yeh BM. Persistent renal enhancement after intra-arterial *vs* intravenous iodixanol administration. *Eur J Radiol* 2011; **80**: 378-386 [PMID: 21470810 DOI: 10.1016/j.ejrad.2011.02.044]

16 **Huo TI**, Wu JC, Lee PC, Chang FY, Lee SD. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. *Liver Int* 2004; **24**: 210-215 [PMID: 15189271 DOI: 10.1111/j.1478-3231.2004.00911.x]

17 **Cho HS**, Seo JW, Kang Y, Bae EJ, Kim HJ, Chang SH, Park DJ. Incidence and risk factors for radiocontrast-induced nephropathy in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization. *Clin Exp Nephrol* 2011; **15**: 714-719 [PMID: 21695415 DOI: 10.1007/s10157-011-0470-9]

18 **Hayakawa K**, Tanikake M, Kirishima T, Yoshinami N, Shintani H, Yamamoto E, Morimoto T. The incidence of contrast-induced nephropathy (CIN) following transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC). *Eur Radiol* 2014; **24**: 1105-1111 [PMID: 24526284 DOI: 10.1007/s00330-014-3099-8]

19 **Wang X**, Erinjeri JP, Jia X, Gonen M, Brown KT, Sofocleous CT, Getrajdman GI, Brody LA, Thornton RH, Maybody M, Covey AM, Siegelbaum RH, Alago W, Solomon SB. Pattern of retained contrast on immediate postprocedure computed tomography (CT) after particle embolization of liver tumors predicts subsequent treatment response. *Cardiovasc Intervent Radiol* 2013; **36**: 1030-1038 [PMID: 23152036 DOI: 10.1007/s00270-012-0506-x]

20 **Herber S**, Biesterfeld S, Franz U, Schneider J, Thies J, Schuchmann M, Düber C, Pitton MB, Otto G. Correlation of multislice CT and histomorphology in HCC following TACE: predictors of outcome. *Cardiovasc Intervent Radiol* 2008; **31**: 768-777 [PMID: 18196335 DOI: 10.1007/s00270-007-9270-8]

21 **Hu J**, Maybody M, Cao G, Wang X, Chen H, Zhu X, Yang R, Wang X. Lipiodol retention pattern assessed by cone beam computed tomography during conventional transarterial chemoembolization of hepatocellular carcinoma: accuracy and correlation with response. *Cancer Imaging* 2016; **16**: 32 [PMID: 27716376 DOI: 10.1186/s40644-016-0090-4]

22 **Yuh BI**, Cohan RH. Different phases of renal enhancement: role in detecting and characterizing renal masses during helical CT. *AJR Am J Roentgenol* 1999; **173**: 747-755 [PMID: 10470916 DOI: 10.2214/ajr.173.3.10470916]

23 **Sheth S**, Fishman EK. Multi-detector row CT of the kidneys and urinary tract: techniques and applications in the diagnosis of benign diseases. *Radiographics* 2004; **24**: e20 [PMID: 14730056 DOI: 10.1148/rg.e20]

24 **Levey AS**, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009; **150**: 604-612 [PMID: 19414839 DOI: 10.7326/0003-4819-150-9-200905050-00006]

25 **Gupta RK**, Bang TJ. Prevention of Contrast-Induced Nephropathy (CIN) in Interventional Radiology Practice. *Semin Intervent Radiol* 2010; **27**: 348-359 [PMID: 22550376 DOI: 10.1055/s-0030-1267860]

26 **Briguori C**, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, Golia B, Ricciardelli B, Condorelli G; REMEDIAL II Investigators. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. *Circulation* 2011; **124**: 1260-1269 [PMID: 21844075 DOI: 10.1161/CIRCULATIONAHA.111.030759]

27 **Solomon R**, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. *N Engl J Med* 1994; **331**: 1416-1420 [PMID: 7969280 DOI: 10.1056/NEJM199411243312104]

28 **Mueller C**, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, Marsch S, Roskamm H. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. *Arch Intern Med* 2002; **162**: 329-336 [PMID: 11822926 DOI: 10.1001/archinte.162.3.329]

29 **Vashishtha D**, McClelland RL, Ix JH, Rifkin DE, Jenny N, Allison M. Relation Between Calcified Atherosclerosis in the Renal Arteries and Kidney Function (from the Multi-Ethnic Study of Atherosclerosis). *Am J Cardiol* 2017; **120**: 1434-1439 [PMID: 28826901 DOI: 10.1016/j.amjcard.2017.07.020]

30 **Roseman DA**, Hwang SJ, Manders ES, O'Donnell CJ, Upadhyay A, Hoffmann U, Fox CS. Renal artery calcium, cardiovascular risk factors, and indexes of renal function. *Am J Cardiol* 2014; **113**: 156-161 [PMID: 24210678 DOI: 10.1016/j.amjcard.2013.09.036]

**Footnotes**

**Institutional review board statement:** The local Institutional Review Board approved this retrospective review (Protocol 16-402) of all patients who underwent hepatic artery embolization (HAE) between January 2010 and January 2011.

**Conflict-of-interest statement:** All authors declare no conflicts of interest related to this article.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** May 27, 2020

**First decision:** June 5, 2020

**Article in press:**

**Specialty type:** Urology and nephrology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** El-Serafy AS **S-Editor:** Zhang L **L-Editor: P-Editor:**

**Figure Legends**

手机屏幕截图

描述已自动生成

**Figure 1 Flow chart of study.** CT: Computed tomography.

图片包含 猫, 照片, 播放, 桌子

描述已自动生成

**Figure 2 Example of Regions-of-interest drawn on the post-embolization non-contrast enhanced computed tomographic to determine the phase of renal enhancement.** ROI 1 measures the Hounsfield units (HU) of the renal cortex. ROI 2 measures the HU of the renal medulla. ROI 3 measures the HU of the renal pelvis. ROI 4 measures the HU of surrounding skeletal muscle. In this example, the renal enhancement phase is late excretory.

图片包含 室内, 照片, 桌子, 食物

描述已自动生成

**Figure 3 Computed tomographic.** A: Immediate post-embolization non-contrast computed tomographic demonstrating homogenous renal parenchymal enhancement (renal cortex and medulla) with Hounsfield units of 172 and incomplete opacification of renal collecting system, consistent with Early Excretory renal enhancement phase. Hyper enhancement of renal parenchyma compared to adjacent paraspinal skeletal muscle is evident; B: Immediate post-embolization non-contrast computed tomographic demonstrating complete opacification of the renal collecting system with renal parenchyma iso-dense to surrounding skeletal muscle, consistent with late excretory renal enhancement phase.

图片包含 室内, 桌子, 小, 覆盖

描述已自动生成

**Figure 4** **Any discernible plaque along the renal arteries with more than 130 Hounsfield units were considered calcifications.** Immediate post-embolization non-contrast computed tomographic demonstrating renal artery calcifications in the right (arrow) (A) and left (arrow) (B) renal arteries.

**Table 1 Patient demographics and baseline characteristics (*n* = 84), patient demographics and baseline characteristics and comorbidities**

|  |  |
| --- | --- |
| **Clinical characteristics** | **Value** |
| Sex |  |
| Male | 53 |
| Female | 31 |
| Age (Yr, average, range) | 63 (29-87) |
| Ethnicity |  |
| Caucasian | 62 |
| African American | 8 |
| Hispanic | 4 |
| Asian | 10 |
| Medical comorbidities |  |
| Diabetes mellitus | 17 |
| CAD/HTN | 29 |
| Cirrhotic? |  |
| Yes | 38 |
| No | 46 |
| Etiology of cirrhosis |  |
| HCV | 16 |
| HBV | 6 |
| EtOH | 4 |
| NASH | 3 |
| Hemochromatosis | 1 |
| Unknown | 8 |
| Type of liver malignancy |  |
| Primary |  |
| HCC | 40 |
| Other | 5 |
| Secondary |  |
| NET | 20 |
| GIST | 4 |
| Other | 15 |
| Number of treatments (*n* = 106) |  |
| 1 | 66 |
| 2 | 14 |
| 3 | 4 |

CAD: Coronary artery disease; HTN: Hypertension; HCV: Hepatitis C virus; HBV: Hepatitis B virus; EtOH: Alcoholic cirrhosis; NASH: Non Alcoholic Steato Hepatitis; HCC: Hepatocellular carcinoma; NET: Neuroendocrine tumor; GIST: Gastrointestinal stromal tumor.

**Table 2 Non-contrast computed tomographic findings and their association with contrast-induced nephropathy development**

|  |  |  |  |
| --- | --- | --- | --- |
| **Association between** **non-contrast CT findings and CIN (*n* = 106)** | | | |
| Renal enhancement pattern | Group A (*n* = 11) (%) | Group B (*n* = 95) (%) | *P* value |
| Early excretory | 6 (55%) | 2 (2%) | < 0.001 |
| Late excretory | 5 (45%) | 93 (98%) |
| Renal artery calcifications | Group A | Group B |  |
| Yes | 6 (55%) | 20 (21%) | 0.01 |
| No | 5 (45%) | 75 (79%) |

CT:Computed tomography; CIN: Contrast-induced nephropathy.